In the current study, we explored the impact of GSK-J4, a candidate inhibitor that could be used as a complement to BTK inhibitors, on the adhesion of MCL cells to stromal cells using an in vitro cell adhesion assay. This evidence concerns the gene BTK and mantle cell lymphoma.